Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Inclusion Criteria:

• Eligible patients are ≥18 years, diagnosed with HCC confirmed by histopathology orcytology, with no prior targeted or immune checkpoint therapy for HCC, and haveundergone curative ablation with no residual lesions according to imaging orpathological assessment. Patients are at high risk of recurrence meeting one of thefollowing criteria: solitary tumor >2cm but ≤5cm, or multiple tumors ≤4tumors and all≤5cm； poor tumordifferentiation； macrovascular invasion of the portal vein(Vp1/Vp2) ； the absence orinfiltration of a tumor capsule ； AFP≥32ng/ml； HBV DNA ≥105IU/ml； history of recurrenceafter curative treatment； family history of tumors.

Exclusion Criteria: Concurrent with other primary malignant tumors; severe coagulation dysfunction or severethrombocytopenic purpura; There is serious infection or organ failure; have previouslyreceived targeted drugs or other PD-1 antibody therapy;